The phase 3 trials will assess Epidiolex over 14 weeks in a randomised, double-blind, placebo-controlled study, enrolling paediatric patients aged one to 18. It is hoped that Epidiolex will ease symptoms associated with Doose syndrome (EMAS), a rarer type of childhood-onset epilepsy, accounting for 1-2% of all cases.
Epidiolex, developed by GW Pharmaceuticals, is an epilepsy treatment derived from cannabidiol (CBD), a chemical component of cannabis. However, it doesn’t include tetrahydrocannabinol (THC), the psychoactive compound cannabis is more well known for.
